Cutaneous melanoma
Adult: Adjuvant treatment in patients with pathologic involvement of regional lymph nodes of >1 mm who have undergone complete resection, including total lymphadenectomy: As monotherapy: 10 mg/kg every 3 weeks for up to 4 doses, followed by 10 mg/kg every 12 weeks for up to 3 years. Doses are given via infusion over 90 minutes. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Intravenous
Metastatic melanoma, Unresectable melanoma
Adult: As monotherapy: 3 mg/kg every 3 weeks via infusion over 30 minutes for a total of 4 doses. In combination with nivolumab: 3 mg/kg every 3 weeks via infusion over 30 minutes for up to 4 doses or until unacceptable toxicity; followed by nivolumab monotherapy until disease progression or unacceptable toxicity (refer to specific product information of nivolumab for dosage recommendations). Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Child: As monotherapy: ≥12 years Same as adult dose. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Child: As monotherapy: ≥12 years Same as adult dose. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Intravenous
Advanced renal cell carcinoma
Adult: As 1st-line treatment of intermediate- or poor-risk cases: In combination with nivolumab: 1 mg/kg every 3 weeks via infusion over 30 minutes for up to 4 doses; followed by nivolumab monotherapy until disease progression or unacceptable toxicity (refer to specific product information of nivolumab for dosage recommendations). Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Intravenous
Hepatocellular carcinoma
Adult: For patients who have been previously treated with sorafenib: In combination with nivolumab: 3 mg/kg every 3 weeks via infusion over 30 minutes for 4 doses; followed by nivolumab monotherapy until disease progression or unacceptable toxicity (refer to specific product information of nivolumab for dosage recommendations). Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Intravenous
Unresectable malignant pleural mesothelioma
Adult: As 1st-line treatment: In combination with nivolumab: 1 mg/kg every 6 weeks via infusion over 30 minutes until disease progression, unacceptable toxicity, or for up to 2 years in patients without disease progression. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Intravenous
Microsatellite instability-high metastatic colorectal cancer
Adult: For the treatment of cases that have progressed after therapy with fluoropyrimidine, oxaliplatin, and irinotecan: In combination with nivolumab: 1 mg/kg every 3 weeks via infusion over 30 minutes for 4 doses; followed by nivolumab monotherapy until disease progression or unacceptable toxicity (refer to specific product information of nivolumab for dosage recommendations). Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Child: ≥12 years Same as adult dose. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Child: ≥12 years Same as adult dose. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Intravenous
PD-L1 expression in metastatic non-small cell lung carcinoma
Adult: As 1st-line treatment in patients whose tumours express PD-L1 (≥1%) as determined by an approved test, with no EGFR or ALK genomic tumour aberrations: In combination with nivolumab: 1 mg/kg every 6 weeks via infusion over 30 minutes until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).
Intravenous
Metastatic non-small cell lung carcinoma
Adult: As 1st-line treatment in patients whose tumours have no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation: In combination with nivolumab and 2 cycles of platinum-based chemotherapy: 1 mg/kg every 6 weeks via infusion over 30 minutes until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guidelines).